Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

Marcum completes merger with NY company

Marcum LLP, an accounting firm with offices in New Haven, has completed its merger with New York-based Friedman LLP. The new firm, called Marcum, now operates in...

| By Caitlin Truesdale

FDA approves BI treatment for pustular psoriasis

Boehringer Ingelheim reports that the FDA has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel,...

| By Caitlin Truesdale

CaroGen to present at World Vaccine Congress

CaroGen reports that Bijan Almassian, PhD, President & CEO, and Timur Yarovin-sky, MD, PhD, Vice President of Discovery, have been invited to speak at The World...

| By Caitlin Truesdale

UConn researchers to expand knowledge of RNA

The National Human Genome Research Institute has awarded genomics expert Brent Graveley and his team $5.6-million to continue to work on an enormous encyclopedia of...

| By Caitlin Truesdale

Medtronic partners with BioIntelliSense re wearable

Medtronic has entered into a strategic partnership with BioIntelliSense for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter...

| By Caitlin Truesdale

Weekly Roundup – September 1, 2022 

View this email in your browser Weekly Roundup – September 1, 2022  UConn’s Office of the Vice President for Research, Technology Commercialization Services (TCS) works with innovators,...

| By Caitlin Truesdale

YNHH to break ground for neuroscience center

Yale New Haven Hospital plans to break ground on its new $838 million neurosciences center at its Saint Raphael campus, two years after delaying the project...

| By Caitlin Truesdale

Bioasis brings hope re rare and orphan diseases

With the acquisition of Phase 2 ready assets from Cresence AS, Bioasis becomes a clinical stage company with a multi-asset pipeline focused on rare and orphan drugs....

| By Caitlin Truesdale

Trevi reports two late-breaking abstracts

Trevi Therapeutics reports that two late-breaking abstracts have been accepted for presentation at upcoming fall medical conferences. The previously disclosed positive interim data from CANAL, a phase...

| By Caitlin Truesdale

Yale team and NIH tackle glioblastoma

A type of tumor called glioblastoma is the most common brain cancer in adults. It’s also one of the most lethal tumor types overall. Only...